Thyroid Eye Disease
📧 Sign up to get email alerts when something new happens for Thyroid Eye Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-09-30Clinical Trial Update: An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED) [Phase 3]
Phase 3 study evaluating VRDN-003 in chronic Thyroid Eye Disease is active but not currently recruiting; no efficacy or safety results are r…
-
CLINICAL_TRIALS research · 2025-09-19Clinical Trial Update: Phase I Clinical Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics of NTB003 in Healthy Participants [Phase 1]
Phase I study to evaluate safety, pharmacokinetics, and pharmacodynamics of NTB003 in healthy participants. Thyroid eye disease is listed as…
-
FDA approval · 2025-09-09FDA Approved: TEPEZZA — Supplemental Application (Horizon Therapeutics USA, Inc.)
FDA approved a supplemental application for TEPEZZA (teprotumumab) submitted by Horizon Therapeutics USA, Inc.
-
CLINICAL_TRIALS trial_result · 2025-09-08Clinical Trial Update: Real World Study to Describe the Effectiveness and Safety of Teprotumumab Among Thyroid Eye Disease Patients
A real-world study completed to evaluate the effectiveness and safety of Teprotumumab in patients with Thyroid Eye Disease.
-
CLINICAL_TRIALS research · 2025-09-03Clinical Trial Update: Evaluation of the Efficacy and Safety Observation of IBI311 Treatment in Patients With Inactive TAO [Phase 4]
Phase 4 clinical trial evaluating the efficacy and safety of IBI311 for inactive Thyroid-associated ophthalmopathy (thyroid eye disease) is …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2025-08-26FDA Approved: TEPEZZA — Supplemental Application (Horizon Therapeutics USA, Inc.)
FDA approved a supplemental application for TEPEZZA (teprotumumab) from Horizon Therapeutics USA, expanding its approved indication for thyr…
-
CLINICAL_TRIALS trial_result · 2025-07-18Clinical Trial Update: A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants With Thyroid Eye Disease (TED) ( THRIVE ) [Phase 3]
A Phase 3 safety, tolerability and efficacy study of Veligrotug (VRDN 001) in healthy volunteers and Thyroid Eye Disease patients (THRIVE) h…
-
CLINICAL_TRIALS research · 2025-07-09Clinical Trial Update: Multi-modal Medical Images for Extraocular Muscle Fibrosis Assessment
This is an update on a completed clinical trial evaluating multi-modal medical imaging to assess extraocular muscle fibrosis in thyroid eye …
-
CLINICAL_TRIALS trial_result · 2025-07-01Clinical Trial Update: Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED) [Phase 1, Phase 2]
ACELYRIN has completed a Phase 1/2 trial evaluating Lonigutamab for Thyroid Eye Disease, with an update highlighting efficacy and safety asp…
-
EMA approval · 2025-04-25First treatment against severe thyroid eye disease
The European Medicines Agency approved Tepezza (teprotumumab) as the first treatment for severe thyroid eye disease, offering significant sy…
-
CLINICAL_TRIALS trial_result · 2025-04-11Clinical Trial Update: Study of ZB001 in Chinese Patients With Thyroid Eye Disease [Phase 1]
Phase 1 study of ZB001 in Chinese patients with Thyroid Eye Disease has completed.
-
CLINICAL_TRIALS trial_result · 2025-02-25Clinical Trial Update: Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) [Phase 2, Phase 3]
An extension study of two doses of Linsitinib for Thyroid Eye Disease is in Phase 2/3 and currently recruiting, sponsored by Sling Therapeut…
-
CLINICAL_TRIALS research · 2025-01-29Clinical Trial Update: A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) [Phase 2, Phase 3]
This document notes an ongoing Phase 2b/Phase 3 trial evaluating linsitinib for Thyroid Eye Disease, currently active but not recruiting.
-
CLINICAL_TRIALS research · 2025-01-10Clinical Trial Update: A Study of SCTT11 in Healthy Participants and Participants with Thyroid Eye Disease. [Phase 1, Phase 2]
A clinical trial update for SCTT11 in healthy participants and Thyroid Eye Disease patients, currently not yet recruiting (Phase 1 and Phase…
-
CLINICAL_TRIALS trial_result · 2025-01-09Clinical Trial Update: A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED) [Phase 3]
A Phase 3 trial evaluating secukinumab 300 mg for Thyroid Eye Disease (Graves' orbitopathy) was terminated, and results have been posted.
-
CLINICAL_TRIALS trial_result · 2024-12-30Clinical Trial Update: A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease [Phase 1, Phase 2]
A Phase 1/2 clinical trial of LASN01 in healthy subjects and patients with pulmonary fibrosis or thyroid eye disease has completed, assessin…
-
CLINICAL_TRIALS trial_result · 2024-12-13Clinical Trial Update: A Multicenter, Open-label Extension Study Evaluating the Efficacy and Safety of IBI311 in Subjects With Thyroid Eye Disease [Phase 3]
A Phase 3 multicenter open-label extension study evaluating the efficacy and safety of IBI311 in subjects with Thyroid Eye Disease (TED).
-
CLINICAL_TRIALS trial_result · 2024-06-21Clinical Trial Update: A Study of TEPEZZA® Treatment in Participants With Thyroid Eye Disease [Phase 1]
Phase 1 study evaluating TEPEZZA in participants with Thyroid Eye Disease has completed.
-
CLINICAL_TRIALS research · 2024-06-20Clinical Trial Update: Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease
Amgen's expanded access protocol for Teprotumumab (HZN-001) to treat active thyroid eye disease (Graves' orbitopathy) has been updated; the …
-
CLINICAL_TRIALS research · 2024-05-14Clinical Trial Update: Study on Efficacy of Add on Selenium in Mild-to-moderate Graves Ophthalmopathy [NA]
This clinical trial is evaluating selenium as an add-on therapy for mild-to-moderate Graves' ophthalmopathy (thyroid eye disease); the study…
-
CLINICAL_TRIALS trial_result · 2024-04-26Clinical Trial Update: A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease [Phase 4]
A Phase 4 study evaluating TEPEZZA (teprotumumab) for chronic inactive thyroid eye disease has been completed, with results posted in April …
-
CLINICAL_TRIALS trial_result · 2024-02-08Clinical Trial Update: A Study of IBI311 in Subjects With Active Thyroid Eye Disease [Phase 2, Phase 3]
A phase 2/3 clinical trial update for IBI311 in active thyroid eye disease has been completed.
-
CLINICAL_TRIALS trial_result · 2023-11-14Clinical Trial Update: Local Betamethasone Versus Triamcinolone Injection in Management of Thyroid Eye Disease [Phase 2, Phase 3]
A completed Phase 2/3 trial comparing local betamethasone versus triamcinolone injection for thyroid eye disease.
-
CLINICAL_TRIALS withdrawal · 2023-09-28Clinical Trial Update: The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease (TED) [Phase 2, Phase 3]
A study evaluating an antioxidant combination (ASTED) for Thyroid Eye Disease was withdrawn during Phase 2/Phase 3.
-
FDA label_change · 2023-07-17FDA Approved: TEPEZZA — Supplemental Application (Horizon Therapeutics USA, Inc.)
The FDA approved a supplemental application for TEPEZZA (teprotumumab) from Horizon Therapeutics USA, Inc., indicating a labeling update.